在患者不耐受多个TKI时,阿斯基米尼布20毫克QD的分子反应
Ruth Stuckey1, Laura Navarrete Bullón1, Asunción Borrero Borrego2,3
1Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
Annals of hematology
|April 7, 2025
概括
一名患有慢性髓性白血病 (CML) 的年轻患者使用低剂量阿西米尼布获得了主要分子响应 (MMR),克服了对其他治疗方法的不耐受. 这证明了药物的药物.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
背景情况:
- 慢性髓性白血病 (CML) 的治疗通常涉及铁酶抑制剂 (TKIs).
- 患者对标准TKI剂量的不耐受性和耐药性带来了重大治疗挑战.
- 阿西米尼布是一种新的TKI,向CML中的BCR-ABL1蛋白.
研究的目的:
- 报告阿斯基米尼布在CML患者中亚治疗剂量的疗效,该患者不能耐受全剂量阿斯基米尼布和之前的TKIs.
- 突出阿西米尼布在挑战性患者群体中治疗CML的潜力.
主要方法:
- 一个年轻的CML患者的病例报告.
- 用20毫克每天一次 (QD) 的阿斯基米尼布剂量治疗,这是次治疗剂量.
- 监测患者的血液样本和分子反应 (MR).
主要成果:
- 患者在治疗四个月内实现了主要分子响应 (MMR).
- 在TKI暂停后,骨髓毒性迅速消失,降低剂量的阿西米尼布允许持续治疗.
- 这是第一个报告的病例,证明阿司明尼布在20毫克QD时有效.
结论:
- 在不耐受标准剂量的CML患者中,亚西明尼布的次治疗剂量可以有效.
- 阿西米尼布为克服CML治疗耐药性和不耐受性提供了一个有前途的治疗选择.
- 对于难以治疗的CML病例,需要对低剂量阿西米尼布治疗方案进行进一步的研究.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147


